In a study published December 31, 2020, in the Journal of Nuclear Medicine, researchers prospectively evaluated more than 300 patients undergoing evaluation for suspected lung cancer and found that FDG-PET/CT-guided biopsies found a statistically significant greater percentage of malignant lesions than invasive procedures guided by CT alone. The clinical benefit of PET/CT biopsy guidance is quicker and more appropriate treatment for patients with suspected lung cancer. "Our results may influence the decision of the preferred method for guidance of percutaneous biopsy of lung lesions, if both PET/CT and CT are available," wrote the researchers, led by first author Dr. Juliano Julio Cerci, PhD, from Quantum Diagnostic Imaging in Curitiba, Brazil.